Physician profile
Bradley Reddick
NPI 1457361859
$2,867.22
in general payments reported to CMS, 2019-2025
25 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $123 · 2021: $302 · 2022: $1,644 · 2023: $62.62 · 2024: $124 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,317.83 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $462.30 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $284.75 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $115.92 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $93.80 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.67 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $68.90 | 2019-2025 | Spravato |
| Neurocrine Biosciences, INC. | $63.95 | 2019-2025 | |
| Lundbeck LLC | $47.36 | 2019-2020 | |
| Alkermes, INC. | $44.60 | 2021-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $35.09 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $29.01 | 2025 | Loreev Xr |
| Vertical Pharmaceuticals, LLC | $28.41 | 2019-2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $24.96 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $22.71 | 2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $20.83 | 2025 | Azstarys |
| Brainsway USA INC | $17.59 | 2023 | |
| Adlon Therapeutics L.P. | $17.14 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.26 | 2019 | |
| Shire North American Group INC | $14.70 | 2019 | |
| Tris Pharma INC | $14.03 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.94 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.80 | 2021 | |
| Eisai INC. | $11.66 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Reddick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.